vs
AST SpaceMobile, Inc.（ASTS）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
AST SpaceMobile, Inc.的季度营收约是REGENXBIO Inc.的1.8倍（$54.3M vs $30.3M），AST SpaceMobile, Inc.净利率更高（-136.2% vs -221.3%，领先85.1%），AST SpaceMobile, Inc.同比增速更快（2758.2% vs 43.0%），REGENXBIO Inc.自由现金流更多（$-52.8M vs $-330.7M）
AST SpaceMobile是总部位于美国得克萨斯州米德兰的上市卫星设计与制造企业，目前正搭建SpaceMobile卫星星座，打造可直接对接未改装普通智能手机的天基蜂窝宽带网络，面向全球偏远及通信服务薄弱地区提供4G、5G宽带覆盖服务。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
ASTS vs RGNX — 直观对比
营收规模更大
ASTS
是对方的1.8倍
$30.3M
营收增速更快
ASTS
高出2715.2%
43.0%
净利率更高
ASTS
高出85.1%
-221.3%
自由现金流更多
RGNX
多$277.9M
$-330.7M
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $54.3M | $30.3M |
| 净利润 | $-74.0M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | -175.0% | -190.0% |
| 净利率 | -136.2% | -221.3% |
| 营收同比 | 2758.2% | 43.0% |
| 净利润同比 | -106.3% | -31.2% |
| 每股收益（稀释后） | — | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASTSRGNX
| Q4 25 | $54.3M | $30.3M | ||
| Q3 25 | $14.7M | $29.7M | ||
| Q2 25 | — | $21.4M | ||
| Q1 25 | — | $89.0M | ||
| Q4 24 | — | $21.2M | ||
| Q3 24 | — | $24.2M | ||
| Q2 24 | — | $22.3M | ||
| Q1 24 | — | $15.6M |
净利润ASTSRGNX
| Q4 25 | $-74.0M | $-67.1M | ||
| Q3 25 | $-122.9M | $-61.9M | ||
| Q2 25 | — | $-70.9M | ||
| Q1 25 | — | $6.1M | ||
| Q4 24 | — | $-51.2M | ||
| Q3 24 | — | $-59.6M | ||
| Q2 24 | — | $-53.0M | ||
| Q1 24 | — | $-63.3M |
毛利率ASTSRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率ASTSRGNX
| Q4 25 | -175.0% | -190.0% | ||
| Q3 25 | -1109.0% | -176.3% | ||
| Q2 25 | — | -296.3% | ||
| Q1 25 | — | 13.6% | ||
| Q4 24 | — | -242.1% | ||
| Q3 24 | — | -256.6% | ||
| Q2 24 | — | -251.3% | ||
| Q1 24 | — | -408.8% |
净利率ASTSRGNX
| Q4 25 | -136.2% | -221.3% | ||
| Q3 25 | -833.7% | -208.3% | ||
| Q2 25 | — | -331.8% | ||
| Q1 25 | — | 6.8% | ||
| Q4 24 | — | -241.3% | ||
| Q3 24 | — | -246.3% | ||
| Q2 24 | — | -237.7% | ||
| Q1 24 | — | -405.4% |
每股收益（稀释后）ASTSRGNX
| Q4 25 | — | $-1.30 | ||
| Q3 25 | — | $-1.20 | ||
| Q2 25 | — | $-1.38 | ||
| Q1 25 | — | $0.12 | ||
| Q4 24 | — | $-0.99 | ||
| Q3 24 | — | $-1.17 | ||
| Q2 24 | — | $-1.05 | ||
| Q1 24 | — | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $4.3B | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.4B | $102.7M |
| 总资产 | $5.0B | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ASTSRGNX
| Q4 25 | $4.3B | $230.1M | ||
| Q3 25 | $2.4B | $274.2M | ||
| Q2 25 | — | $323.3M | ||
| Q1 25 | — | $267.9M | ||
| Q4 24 | — | $234.7M | ||
| Q3 24 | — | $255.5M | ||
| Q2 24 | — | $290.4M | ||
| Q1 24 | — | $338.7M |
股东权益ASTSRGNX
| Q4 25 | $2.4B | $102.7M | ||
| Q3 25 | $1.6B | $161.5M | ||
| Q2 25 | — | $213.7M | ||
| Q1 25 | — | $274.2M | ||
| Q4 24 | — | $259.7M | ||
| Q3 24 | — | $301.4M | ||
| Q2 24 | — | $348.3M | ||
| Q1 24 | — | $390.7M |
总资产ASTSRGNX
| Q4 25 | $5.0B | $453.0M | ||
| Q3 25 | $2.6B | $525.2M | ||
| Q2 25 | — | $581.0M | ||
| Q1 25 | — | $490.9M | ||
| Q4 24 | — | $466.0M | ||
| Q3 24 | — | $519.1M | ||
| Q2 24 | — | $569.4M | ||
| Q1 24 | — | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $65.0M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $-330.7M | $-52.8M |
| 自由现金流率自由现金流/营收 | -609.0% | -174.0% |
| 资本支出强度资本支出/营收 | 728.7% | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-790.4M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流ASTSRGNX
| Q4 25 | $65.0M | $-52.3M | ||
| Q3 25 | $-64.5M | $-56.0M | ||
| Q2 25 | — | $-49.3M | ||
| Q1 25 | — | $33.6M | ||
| Q4 24 | — | $-31.6M | ||
| Q3 24 | — | $-40.5M | ||
| Q2 24 | — | $-45.5M | ||
| Q1 24 | — | $-55.5M |
自由现金流ASTSRGNX
| Q4 25 | $-330.7M | $-52.8M | ||
| Q3 25 | $-302.9M | $-56.5M | ||
| Q2 25 | — | $-49.7M | ||
| Q1 25 | — | $32.6M | ||
| Q4 24 | — | $-32.7M | ||
| Q3 24 | — | $-40.9M | ||
| Q2 24 | — | $-46.0M | ||
| Q1 24 | — | $-56.0M |
自由现金流率ASTSRGNX
| Q4 25 | -609.0% | -174.0% | ||
| Q3 25 | -2055.0% | -189.9% | ||
| Q2 25 | — | -232.8% | ||
| Q1 25 | — | 36.6% | ||
| Q4 24 | — | -154.2% | ||
| Q3 24 | — | -168.9% | ||
| Q2 24 | — | -206.2% | ||
| Q1 24 | — | -358.5% |
资本支出强度ASTSRGNX
| Q4 25 | 728.7% | 1.7% | ||
| Q3 25 | 1617.6% | 1.7% | ||
| Q2 25 | — | 1.8% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | — | 5.1% | ||
| Q3 24 | — | 1.3% | ||
| Q2 24 | — | 2.1% | ||
| Q1 24 | — | 3.6% |
现金转化率ASTSRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASTS
| Products | $44.4M | 82% |
| Other | $7.8M | 14% |
| Sat Co | $2.1M | 4% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
